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Abstract
The over-production of β-amyloid (Aβ) has been strongly correlated to neuronal dysfunction and altered synaptic
plasticity in Alzheimer’s disease (AD). Accordingly, it has been proposed that disrupted synaptic transmission and
neuronal network instability underlie memory failure that is evident in the early phases of AD. Homeostatic synaptic
plasticity (HSP) serves to restrain neuronal activity within a physiological range. Therefore a disruption of this
mechanism may lead to destabilization in synaptic and neural circuit function. Here, we report that during HSP by
neuronal activity deprivation, application of Aβ results in an aberrant over-response of the up-regulation of AMPA
receptor (AMPAR)-mediated synaptic currents and cell-surface AMPAR expression. In the visual cortex, in vivo HSP
induced by visual deprivation shows a similar over-response following an Aβ local injection. Aβ increases the
expression of GluA2-lacking, calcium permeable AMPARs (CP-AMPARs), which are required for the initiation, but not
maintenance of HSP. Both GluA2-lacking and GluA2-containing AMPARs contribute to the Aβ-mediated over-scaling
of HSP. We also find that Aβ induces the dissociation of HDAC1 from the miR124 transcription factor EVI1, leading
to an up-regulation of miR124 expression and increased amount of CP-AMPARs. Thus, via aberrant stimulation of
miR124 expression and biogenesis of CP-AMPARs, Aβ is able to induce an over response in HSP. This Aβ-mediated
dysregulation in homeostatic plasticity may play an important role in the pathogenesis of altered neural function
and memory deficits in the early stages of AD.
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Introduction
Alzheimer’s Disease (AD) is characterized by deficits in
learning and memory with an eventual loss of higher
cognitive functions. Accumulation of β-amyloid (Aβ) in
the brain is a hallmark of AD and studies have demon-
strated that Aβ can induce synapse dysregulation and al-
tered neuronal activity [26, 32, 37, 54, 58]. Emerging
evidence suggests that soluble Aβ oligomers adversely
affect synaptic function, which eventually leads to the
cognitive failure associated with AD [36, 43, 48, 58]. A
key neuropathobiological hallmark in early AD is the ab-
errant regulation in synaptic function including AMPA
receptor (AMPAR) synaptic accumulation and synaptic
plasticity [7, 43]. In vitro studies performed in hippo-
campal neurons have reported that application of Aβ
peptides, at concentrations below neurotoxic levels, can
inhibit LTP induction without affecting basal synaptic
transmission [8, 9, 61]. A similar result was shown in
vivo, where cerebral injection of naturally secreted Aβ
collected from cells expressing amyloid precursor pro-
tein (APP) prevented the stable maintenance of LTP in
the hippocampal CA1 region [58]. In vivo injection of
Aβ is reported to facilitate LTD and LTP reversal (depo-
tentiation) in the CA1 region of the hippocampus [32].
These studies have provided great insight into Hebbian
plasticity in AD, however the role of Aβ in homeostatic
synaptic plasticity (HSP) remains largely unknown [29].
A major function of HSP is to regulate neuronal activity
in a negative feedback manner, thus maintaining neuronal
activity or synaptic function [15, 23] within a physiological
range after changes in network activity [6, 10, 55, 56].
Under chronic suppression of neuronal activity, HSP is
expressed via an increase in synaptic expression of
AMPARs producing an up-scaling of AMPAR-mediated
miniature post-synaptic currents (mEPSCs). While
most studies show inactivity-induced synaptic scaling
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in cultured neurons [2, 46, 50, 55], HSP is also observed
in vivo including in the spinal cord [16, 19, 33, 59] and in
the visual cortex [11, 17, 31, 34, 38]. AMPARs are hetero-
tetrameric ion channels consisting of different composi-
tions of the four subunits GluA1–4, and the most
common of which are GluA1/GluA2 and GluA2/GluA3
combinations [5, 13]. During the early phase of neural
inhibition, a change in GluA2 expression leads to the for-
mation of GluA2-lacking, calcium permeable AMPARs
(CP-AMPARs). The production and insertion of CP-
AMPARs at the synapse is required for the initiation of
HSP. We have recently shown that the brain-enriched
microRNA, miR124, causes a selective reduction in GluA2
levels via interaction with its 3’-UTR, leading to CP-
AMPAR expression and HSP [24].
Here we report that during inactivity-dependent HSP,
either in vitro in cultured neurons with TTX incubation
or in vivo in the visual cortex with visual deprivation,
application of Aβ results in an aberrant over-scaling of
AMPAR-mediated synaptic currents and surface AMPAR
expression. Aβ incubation or brain injection produces the
expression of additional CP-AMPARs under neuronal ac-
tivity inhibition. The CP-AMPARs are required for the ini-
tiation, but not maintenance of HSP. Consistent with this,
both in vitro in cultured neurons with TTX incubation,
and in vivo in the visual cortex during visual deprivation,
application of Aβ leads to increased miR124 expression
and the Aβ-mediated HSP can be blocked by miR124
suppression. Additionally, we show that Aβ induces the
dissociation of HDAC1 from the inhibitory miR124
transcription factor EVI1, producing an up-regulation
of miR124 expression and increased generation of
CP-AMPARs. Thus, Aβ induces an over-response to
inactivity-dependent HSP via an upregulation of
miR124 and CP-AMPAR expression. Therefore in the
presence of Aβ, neurons adapt their synaptic properties
distinctly, which is likely to cause destabilization in neural
network operation and brain function in AD.
Materials and methods
Drugs, antibodies and plasmids
TTX, APV and PhTx were purchased from Sigma Aldrich
and prepared in water. Bicuculline was purchased from
Tocris Bioscience and prepared in DMSO. All drugs were
prepared in a 1000× stock solution, stored in aliquots
at −20°C and thawed only once prior to use to preserve
their potency. GluA1N and GluA2N antibodies (1:500,
Mouse, Millipore) GluA1C (1:500, Rabbit, homemade)
were used for staining AMPARs and probed with
Alexa-fluor conjugated secondary antibodies (1:700,
Invitrogen). EVI1 (Rabbit, Abcam) and HDAC1 (Mouse,
Cell Signaling) were used for co-immunoprecipitation
(1μg) and western blotting (1:1000) experiments. Aβ
(Rabbit, U6590) was a generous gift from the Angela Ho
Lab, Boston University. Two tandem repeats of the
miR124-BS sequence (5’-TGGCATTCACAAGTGCCTT
AA -3’) were cloned into pEGFP-N1. Lentivirus-encoding
a reverse complementary sequence of miR-124 was pur-
chased from Genechem Inc (Shanghai, China).
β-Amyloid. Synthetic Aβ (1–42) was purchased from
Invitrogen and prepared according to the manufacturer’s
instructions. Briefly, the peptide was dissolved in
HPLC grade water at 1mM then diluted to 200 μM in
PBS and incubated at 37°C for 24 h. Samples were ali-
quoted, stored at −20°C, and thawed once directly
prior to use.
Neuronal cultures
Primary hippocampal cultures were prepared from em-
bryonic day 18 rat embryos as previously described [40].
Cells (0.4–0.6 × 106) were plated into a 60-mm dish with
polylysine-precoated coverslips and maintained in neuro-
basal medium that was replenished twice a week. Neurons
were treated and recorded between 14–16 days in vitro
(DIV).
Aβ and drug treatment
Aβ (0.5 μM), TTX (1 μM) or APV (25 μM) were added
directly to the culture medium at 14–15 DIV and
allowed to incubate at 37°C for the time specified prior
to recording. For recovery experiments, neurons were
treated for 24 h with Aβ and/or TTX, washed 3× with
artificial cerebrospinal fluid (ACSF) and fresh culture
medium was replaced for the time indicated.
Immunocytochemistry
Neurons were washed with ACSF and fixed with 4%
paraformaldehyde/4% sucrose for 10 minutes, and
stained without permeabilization for surface labeling.
Coverslips with neurons were blocked with 10% goat
serum in ACSF for 1 h and then incubated with the
GluA1-N terminal and GluA2-N terminal antibodies dis-
solved in 5% goat serum in ACSF for 2 h at room
temperature. Cells were washed three times with PBS
and incubated with fluorescent Alexa-fluor-conjugated
secondary antibodies for 1 h prior to visualization. Cov-
erslips were mounted onto slides with Prolong Gold
Anti-fade Reagent for visualization on the microscope.
Cell death assay
After undergoing the different HSP paradigms, neurons
were treated with propidium iodide (PI, 1μg/mL, Sigma-
Aldrich) to label the nuclei of dying cells and Hoescht
(1μg/mL, Cell Signaling) to label all nuclei. Both PI and
Hoescht were added at the same time, directly to the
culture media, and allowed to incubate for 20 min at
37°C. As a positive control, one set of neurons was
treated with glutamate (30 μM) for 30 min, washed
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with ACSF and the media replaced and returned to
the incubator for 3 hours prior to PI and Hoescht la-
beling. Cells were then washed with ACSF and fixed
with 4% paraformaldehyde/4% sucrose for 10 minutes.
Following a wash with PBS, neuronal coverslips were
mounted onto slides with Prolong Gold Anti-fade Re-
agent for microscopy. The ratio of PI-positive nuclei
to total nuclei (Hoescht) was calculated to determine
the percentage of dying cells.
Image collection and analysis
Mounted coverslips were kept overnight in the dark
at room temperature before imaging with a 63× oil-
immersion objective. A DIC image was taken for morph-
ology purposes and images were collected with Axiovision
4.8 software and exposure time for the fluorescence signal
was adjusted manually so the signals were within a full
dynamic range. Either the glow scale look-up table or the
histogram was used to monitor the saturation level. Once
the parameters were set, they were fixed and used
throughout the experiment. Typically, —three to five
sections of proximal dendrites per cell were used for
analysis. AMPAR clusters were individually inspected to
avoid contamination with nonspecific signals.
For accurate quantification, all images were collected
in 8-bit gray scale and saved for raw data analysis with
Image J software.
A multi-colored image (red and green from stained
glutamate receptors and a DIC image for morphology)
was separated into three channels with Image-J software,
and the windows were synchronized. By tracing a neu-
ron’s dendrites in the DIC channel, the corresponding
postsynaptic AMPAR clusters were able to be precisely
located in the red and green channels..
AMPAR puncta size was calculated as the product of
size and fluorescence intensity of each puncta. The data
were presented as averages of AMPAR puncta ± SEM
normalized to controls. Greater than 100 hundred puncta
were measured per cell.
Co-immunoprecipitation and western blot
Two-week-old cultured cortical neurons were incubated
with Aβ and/or TTX for 24 h and harvested in ice-cold
RIPA lysis buffer (40 mM Tris–HCl, 150 mM Nacl, 1%
NP-40, 1% sodium deoxycholate, 0.1% SDS and a protease
inhibitor cocktail containing AEBSF, Aprotinin, Bedysyin,
E-64, Leupeptin and Pepstatin A, Roche) and rotated at
4 °C for 45 min. Following centrifugation of the lysates at
13,000g for 15 min, supernatants were incubated over-
night on rotation at 4 °C with anti-EVI1 antibodies, (1 μg,
Abcam) followed by the addition of 60 μl of 50% slurry of
protein A-Sepharose beads (Santa Cruz Biotechnology).
Immunoprecipitates were washed three times with lysis
buffer and resuspended in 60 μl of 2 × Laemmli buffer and
denatured on a 95 °C heat block for 10 min. Immunopre-
cipitates were analysed by western blotting. For western
blot of Aβ species, prepared Aβ oligomers were run
on 4–20% gradient TGX gels (Biorad) and transferred
to PVDF membranes.
Electrophysiology
For in vitro mEPSC recordings, 14–15 DIV cultured hip-
pocampal neurons were treated with TTX (1μM) for 24
h to induce HSP. The coverslip was then transferred to a
recording chamber with an extracellular solution con-
taining (in mM): 140 NaCl, 3 KCl, 1.5 MgCl2, 2.5 CaCl2,
11 glucose, and 10 HEPES (305 mOsm, pH 7.4,), which
was supplemented with TTX (1μM) to block action
potentials, APV (50 μM) to block NMDARs and bicu-
culline (20 μM) to block GABAA receptor-mediated
currents. To block CP-AMPARs, recordings were made
in the presence of Philanthotoxin (PhTx, 2 μM) in the
extracellular solution. Whole cell voltage-clamp re-
cordings were made with patch pipettes filled with
intracellular solution containing (in mM): 110 Cs-
methanesulfonate, 10 CsCl, 10 Hepes, 0.2 EGTA, 4
Mg-ATP, 0.3 Na2-GTP, and 10 sodium phosphocreatine
(295 mOsm, pH 7.4), with the membrane potential
clamped at −70mV. Recordings started 5 minutes after es-
tablishing whole-cell configuration to ensure equilibration
between the pipette solution and the cytosol. Series resist-
ance for recordings ranged between 10–15 MΩ and cell
capacitance values were between 85–150 pF. mEPSCs
were recorded with an Axopatch 200B amplifier and dis-
played and recorded digitally on a computer for subse-
quent off-line analysis with Clampfit.
Templates for a typical mEPSC were created using
Clampfit software that averaged 25 manually selected
typical events. The templates were used to scan the
traces for events with highly similar kinetics and a mov-
ing baseline was created from each event to calculate
amplitude. Data was then manually inspected for selec-
tion of typical mEPSC events. All data were presented as
normalized mean ± SEM. For cumulative probabilities,
the relationship between control and experimental amp-
litude and inter-event interval distributions were deter-
mined by ranking an equal number of randomly selected
values from all cells recorded from each condition in as-
cending order. These amplitude distributions were
linearly interpolated to plot each condition.
To calculate the ratio of CP-AMPAR current to total
AMPAR current, the amplitude of neurons recorded
without PhTx was subtracted from the amplitude of re-
cordings in the presence of PhTx and divided by the
amplitude of recordings performed without PhTx. To
calculate N-AMPAR current, the amplitudes of record-
ings in the presence of PhTX was used.
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For in vivo recordings, brain slice sections (300 μm) of
the visual cortex (V1 area) were prepared using a vibra-
tory microtome. Slices were allowed to recover at 32°C
for 30 min then at room temperature for at least 1 h.
The composition of ACSF (in mM) was 124 NaCl, 3
KCl, 1.25 NaH2PO4, 1.2 MgCl2, 2 CaCl2, 26 NaHCO3,
and 10 dextrose (305 mOsm, pH 7.4). Brain slices were
transferred to a recording chamber and continuously
superfused with ACSF (2 ml/min) saturated with 95%
O2 and 5% CO2 supplemented with TTX (1μM), APV
(50μM) and bicuculline (20μM) and maintained at room
temperature. To block calcium-permeable AMPARs,
philanthotoxin (5 μM) was added into the extracellular
solution.
Brain slices were visualized with IR-DIC using an
Axioscope 2FS equipped with Hamamatsu C2400-07E
optics. Recording electrodes were filled with an internal
solution containing (in mM): 140 K-gluconate, 10 Hepes,
0.2 EGTA, 2 NaCl, 2 MgATP, 0.3 NaGTP Miniature
events from each trace (>300 consecutive events) were
identified using template matching in Clampfit software
(Molecular Devices) with a threshold of 5 pA, 20%–80%
rise time of less than 1 ms and manually confirmed for
analysis. All data were acquired at 10 kHz and filtered
with a lowpass filter at 2 kHz.
Visual deprivation
Mice (30 ± 5 days old) were anesthetized with 6% chloral
hydrate (6ml/kg; i.p.) and the eyelids were covered with
a black pellicle of appropriate size. Black ink powder is
mixed with an epoxy adhesive (AB gel) to bond the
black pellicle to the closed eyelids. The adhesive was ap-
plied across the neck, avoiding the leg, to stabilize the
pellicle. After waking up, a powerful light was used to
make sure that the visual deprivation procedure was suc-
cessful. All mice were held for 24 h in a darkroom prior
to electrophysiological recordings. Control animals were
raised with a normal light cycle (12 h light/dark). Mice
were injected with Aβ oligomers (10 μg) in the V1 re-
gion (ML ±2.3 mm, AP 3.16 mm, DV 0.9 mm) followed
by binocular visual deprivation [3].
Total RNA extraction and quantitative real-time PCR
Total RNA was purified using TRIzol (Thermo Fisher)
and treated with DNAseI (Thermo Fisher) to remove
DNA contamination from hippocampal cultures. Total
RNA was recovered from 60 mm culture dishes and
purity was confirmed with an optical density A260/
A280 ratio >1.9. To analyze the expression levels of
the mature miR124 sequence (5T- UGUGUUCACAGU
GGACCUUGAU −3’), 2 μg of total RNA was reverse tran-
scribed and quantitative real-time PCR (qRT-PCR) was
performed with a 7300 real-time PCR system (Applied
Biosystems) using a TaqMan mir124 assay kit (Applied
Biosystems. Cat. #: 4426961). Transcript levels were




using a micro RNA Taqman assay (Applied Biosystems,
Cat. # 4427975).
Animals for visual deprivation
Mice (male C57BL/6J mice, 80 ± 2 days older) were
raised with a normal light cycle (12 h light/dark). The
mice were anesthetized with 6% chloral hydrate (0.06ml/
10 g; i.p.). Mice were injected with Aβ oligomers (10 μg)
in the V1 region (ML 2.3, AP 3.16, DV 0.9) and then
underwent the visual deprived procedure. This study
was approved by the Animal Care and Use Committee
of Tongji Medical College.
Statistics
Statistical analysis was performed with GraphPad Prism
6 software using a Kruskal-Wallis non-parametric test to
check for significance followed by the Mann–Whitney U
to test between group comparisons, with a Bonferoni
correction for multiple comparisons where appropriate.
Results
Aβ causes over-scaling during inactivity-dependent HSP
To assess the effect of Aβ on HSP during activity
deprivation, Aβ oligomers (0.5 μM) were applied to
cultured rat hippocampal neurons, with TTX (1 μM) or
vehicle (water), for 24 h and AMPAR-mediated mEPSCs
were recorded (Fig. 1a1). The Aβ (1–42) monomer was
allowed to aggregate into oligomeric species during
preparation and confirmed via western blot (Additional
file 1: Figure S1). In a typical HSP response after TTX
incubation, we observed a 39% increase in mEPSC amp-
litude. Consistent with previous reports, Aβ treatment
led to a modest but significant decrease in mEPSC amp-
litude after 24 h [7, 14]. Strikingly, when Aβ was co-
applied together with TTX (TTX/Aβ) in neurons, we
found that mEPSCs were increased to approximately
60% in amplitude, a response significantly stronger than
a regular HSP response by TTX alone (Fig. 1a2–a3).
Additionally, using a different paradigm in which HSP
was induced with the application of TTX and the
NMDA receptor antagonist APV (25 μM), we found that
co-application of Aβ produced a 22% greater increase in
mEPSC amplitude compared to treatment with TTX +
APV alone (Additional file 1: Figure S2). Therefore, in
the presence of Aβ, activity deprivation induced over-
scaling of mEPSC during homeostatic regulation. A
rightward shift in the cumulative distribution of mEPSC
amplitudes (Fig. 1b) was not accompanied by any
changes in inter-event interval (Fig. 1c) or frequency
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(Additional file 1: Figure S3), suggesting a predominant
postsynaptic change in AMPA receptor currents.
Aβ does not alter the set-point of HSP
Homeostatic regulation serves to restrain synaptic activ-
ities within a physiological range from a certain thresh-
old, or a set-point. It is possible that the Aβ-mediated
over-scaling of HSP was due to a shift in the homeo-
static set-point to a higher level. If so, the synaptic
strength may not return to basal levels, even after activ-
ity inhibition. To investigate whether TTX/Aβ-mediated
HSP was reversible, we removed the treatment medium,
washed the neurons and incubated the cells in fresh
media after HSP for various lengths of time (Fig. 2a1).
24 h following TTX/Aβ removal, mEPSC amplitudes
showed a significant reduction; after 96 h, mEPSC am-
plitudes of both TTX- and TTX/Aβ-treated neurons
returned to basal levels (Fig. 2a2). Therefore, the Aβ-
mediated over-scaling of HSP was reversible and seemed
to not affect the homeostatic set-point.
To investigate whether Aβ could induce neuronal tox-
icity during activity deprivation, we performed a cell
death assay after 24 hr incubation with Aβ, TTX or
TTX/Aβ. Live neurons were treated with propidium
iodide (PI) to label dying cells and Hoescht to label all
nuclei, with or without a 30uM glutamate challenge to
induce excitotoxicity. Quantification of the ratio of PI-
positive to Hoescht positive nuclei showed that activity
deprivation induced more cell death after a glutamate
challenge, however cells treated with Aβ did not showed
increased excitotoxicity (Additional file 1: Figure S4).
CP-AMPARs regulate the Aβ-mediated over-scaling
GluA2-lacking CP-AMPARs are produced and required
for the expression of HSP during activity deprivation
[25, 30, 39, 53]. To examine the role of CP-AMPARs in
Aβ-mediated over-scaling, neurons were treated with
TTX or TTX/Aβ with or without the selective CP-
AMPAR antagonist, philanthotoxin (PhTx), for 24 h
(Fig. 2b1). Inhibition of CP-AMPARs during neuronal
inactivity was sufficient to block both TTX- and TTX/
Aβ -induced HSP in mEPSCs (B2). Thus, the Aβ-
triggered over-scaling shared the same requirement for
CP-AMPARs as regular HSP. Previous studies indicate
Fig. 1 Aβ triggers an aberrant homeostatic response during neuronal activity deprivation. a1 Treatment paradigm. Neurons were treated with Aβ
alone, TTX alone, or TTX and Aβ together (TTX/Aβ) for 24 h prior to mEPSC recordings. a2 Sample mEPSC traces showing Aβ-mediated HSP.
a3 Quantification of mEPSC amplitudes (control = 12.9 ± 0.75, n = 9; Aβ = 10.9 ± 0.79, n = 9; TTX = 17.7 ± 0.67, n = 7; TTX/Aβ = 20.6 ± 0.82, n = 8.
b, c Cumulative probability plots showing no change in inter-event interval (b) and a typical multiplicative scaling effect on mEPSC amplitude (c).
Mann–Whitney U test. *p < 0.05, **p < 0.01, ***p < 0.001
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Fig. 2 (See legend on next page.)
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that CP-AMPARs are required for HSP initiation [16, 17,
23, 24] however their role in the expression stage (after
initiation) of HSP remains unclear. We therefore treated
neurons with TTX for 12 h (for HSP initiation), followed
by 12 h incubation with TTX + PhTx (Fig. 2c1). mEPSC
recordings from these neurons showed that PhTx applica-
tion at a later stage did not affect synaptic scaling
(Fig. 2c2), indicating that CP-AMPARs were necessary
only for the initiation, but not the maintenance of HSP.
To investigate whether Aβ-mediated over-scaling was
dependent on CP-AMPARs during the later stage of HSP
expression, we recorded from neurons that were incu-
bated with TTX alone for 12 h for normal HSP initiation,
then with TTX/Aβ + PhTx for the subsequent 12 h
(Fig. 2c1). Surprisingly, whereas AMPAR mEPSC ampli-
tudes scaled to levels similar to TTX-mediated HSP, these
neurons failed to produce the Aβ-dependent over-scaling
of HSP (Fig. 2c2) Additionally, after 24 h treatment with
TTX/Aβ, mEPSCs showed a faster decay time (90–10%)
indicative of the presence of GluA2-lacking AMPARs
(Additional file 1: Figure S5). Because TTX treatment
can induce the expression of CP-AMPARs and Aβ
may prolong their expression, we examined whether
treatment of Aβ alone after 12 h incubation with
TTX could produce over-scaling (Fig. 2c1). However,
Aβ treatment after a normal initiation of HSP was
not sufficient to induce over-scaling similar to 24 hr
TTX/Aβ treatment (Fig. 2c2). These findings suggest
that CP-AMPARs play a role in the Aβ-mediated
over-response of the later expression stage of HSP
during periods of inactivity.
Both GluA2-containing and GluA2-lacking AMPARs
contribute to Aβ-induced over-scaling
We next sought to characterize the relative contribution
of GluA2-containing, normal AMPARs (N-AMPARs)
and CP-AMPARs to the mEPSC currents during HSP.
We have shown that CP-AMPARs are required for HSP
initiation in TTX and TTX/Aβ treated neurons, but
whether the additional currents in over-scaling came en-
tirely from CP-AMPARs was not clear. Aβ may facilitate
CP-AMPAR expression only transiently during initiation
resulting in stronger HSP responses by recruiting more
N-AMPARs to synapses during the later stage of HSP.
Alternatively, Aβ could simply trigger continuous ex-
pression of CP-AMPARs over the entire course, includ-
ing the early initiation stage and later maintenance
stage. To investigate these possibilities, neurons were
treated with TTX or TTX/Aβ for 8 or 24 h to allow HSP
expression. mEPSC recordings were then conducted
either in the presence of PhTx to block CP-AMPARs, or
without PhTx to record total AMPAR currents (N-
AMPAR + CP-AMPAR). The difference between the two
recording conditions would indicate the net contribution
of CP-AMPARs. With this approach, we were able to
compare the relative contribution of N-AMPARs and
CP-AMPARs during the early initiation (8 h) (Fig. 3a1)
and the later (24 h) (Fig. 3b1) stages of HSP. After 8 h
treatment with TTX or TTX/Aβ, both conditions
showed a ~10% increase in mEPSC amplitude over con-
trols, and addition of PhTx during recordings reduced
amplitudes back to control levels (Fig. 3a2), indicating
that the small increase in mEPSC amplitude during HSP
initiation predominantly resulted from addition of CP-
AMPARs in both TTX and TTX/Aβ treated neurons.
Thus, the Aβ-mediated over-scaling was not due to an
earlier, or stronger, onset during the HSP initiation. In
contrast, when neurons were treated for 24 h with TTX
or TTX/Aβ, addition of PhTx during recordings produced
a 23% decrease in mEPSC amplitude in TTX/Aβ treated
neurons, compared to a 12% decrease in neurons treated
with TTX alone (Fig. 3b2 and 3c). TTX/Aβ treatment
therefore resulted in larger amounts of CP-AMPAR ex-
pression during the later stage of HSP (Fig. 3d).
Analysis of the ratio of CP-AMPAR to total AMPAR
currents showed a larger contribution of CP-AMPARs
after Aβ treatment during activity deprivation (Fig. 3e).
A comparison of N-AMPAR currents also showed a 20%
increase in TTX/Aβ-treated neurons over TTX-treated
neurons (Fig. 3f ). These results demonstrate that in
addition to a modest increase in CP-AMPARs, more N-
AMPARs were added during the expression stage of Aβ-
(See figure on previous page.)
Fig. 2 Recovery time course and requirement of CP-AMPARs for HSP. a1 Treatment paradigm for HSP recovery. Neurons were incubated in the
appropriate treatment for 24 h, washed, then allowed to recover in fresh medium for various lengths of time. a2 Normalized mEPSC amplitudes
after recovery for 24 and 96 h. Both the TTX and TTX/Aβ treatment groups returned to baseline after 96 h recovery, indicating a lack of change in
the set point of neuronal activity during basal conditions (control = 12.7 ± 0.62, n = 9; TTX = 16.9 ± 0.56, n = 13; TTX 24 h recovery = 15.8 ± 0.51, n = 9;
TTX 96 h recovery = 15.9 ± 1.33, n = 8; TTX/Aβ = 19.6 ± 0.54, n = 10; TTX/Aβ 24 h recovery = 17.7 ± 0.59, n = 9; TTX/Aβ 96 h recovery = 15.8 ± 1.51, n = 8).
b1 Treatment paradigm of PhTx application during HSP. b2 Graph of normalized mEPSC amplitudes showing that blockade of CP-AMPARs was suffi-
cient to occlude HSP in both the TTX and TTX/Aβ treatment groups (control = 12.5 ± 0.28, n = 7; TTX = 17.1 ± 0.52, n = 5; TTX + PhTx = 13.1 ± 0.42, n = 6;
TTX/Aβ = 19.6 ± 0.79, n = 6; TTX/Aβ + PhTx = 13.5 ± 0.28, n = 6). c1 Paradigm of PhTX application after the initiation phase of HSP. Neurons were
allowed to initiate HSP normally in the presence of TTX and then treated with PhTx ± Aβ. c2 Graphs show that blockade of CP-AMPARs after typical
HSP initiation was sufficient to occlude Aβ-induced over-scaling of HSP (control = 12.4 ± 0.50, n = 7; TTX = 17.1 ± 0.65, n = 6; TTX→ PhTx = 16.9 ± 0.68,
n = 7; TTX/Aβ = 20.1 ± 0.83, n = 6; TTX/Aβ→ PhTx = 17.6 ± 0.38, n = 8 cells). Mann–Whitney U test, * p < 0.05, ** p < 0.01, *** p < 0.001, ns:
not significant








Fig. 3 Both CP-AMPAR and N-AMPARs contribute to the Aβ-mediated over-scaling of HSP. a1 and b1 Treatment paradigms. mEPSCs were recorded
in the presence of PhTx after 8 h (a1) and 24 h (b1) of TTX or TTX/Aβ incubation. a2 and b2 Normalized mEPSC amplitudes after 8h (a2) (control =
12.5 ± 0.42, n = 10; Con→ PhTx = 12.1 ± 0.51, n = 10; 8h TTX = 13.9 ± 0.58, n = 8; 8h TTX→ PhTx = 12.2 ± 0.72, n = 8; 8 h TTX/Aβ = 13.9 ± 0.63, n = 9; 8 h
TTX/Aβ→ PhTx = 12.5 ± 0.66; n = 9) and 24 h (b2) HSP (control = 12.1 ± 0.60, n = 9; control→ PhTx = 11.7 ± 0.43, n =9; TTX = 16.6 ± 0.59, n = 8; TTX→
PhTx = 15.1 ± 0.76, n = 8; TTX/Aβ = 19.9 ± 0.52, n = 9; TTX/Aβ→ PhTx = 17.1 ± 0.78; n = 9). PhTx was only applied to the extracellular recording solution
at the time of the recording. c Sample traces of mEPSCs after 24 h application of the indicated treatments. d Stacked graph of the relative contribu-
tions of N-AMPARs (mEPSC amplitude after application of PhTx) vs. CP-AMPARs (mEPSC amplitude without PhTx− amplitude with PhTx). Application
of Aβ caused an increase in both CP-AMPAR and N-AMPAR components in HSP (control CP-AMPAR = 0.01 ± 0.04, n = 7; control N-AMPAR = 0.98 ± 0.05,
n = 7; TTX CP-AMPAR = 0.11 ± 0.04, n = 7; TTX N-AMPAR = 1.28 ± 0.06, n = 7; TTX/Aβ CP-AMPAR = 0.18 ± 0.06, n = 6; TTX/Aβ N-AMPAR = 1.44 ± 0.04,
n = 6). e Percentage of the CP-AMPAR component after 8 h and 24 h HSP. Ratio = (amplitude without PhTx- amplitude with PhTx)/(amplitude without
PhTx) (TTX 0 h = 2.27 ± 1.42%, n= 9; TTX 8 h = 12.14 ± 0.82%, n= 9; TTX 24 h= 13.09 ± 1.99%, n= 8; TTX/Aβ 0 h = 2.52 ± 1.93%, n= 8; TTX/Aβ 8 h = 11.05 ±
2.87%, n= 10; TTX/Aβ 24 h = 18.99 ± 2.13%; n= 10). f Changes in the N-AMPAR current after 8 h and 24 h HSP (TTX 0 h = 1 ± 0.04, n = 9; TTX 8 h = 0.99 ±
0.03, n= 9; TTX 24 h = 1.26 ± 0.03, n= 8; TTX/Aβ 0 h = 1± 0.04, n= 10; TTX/Aβ 8 h = 1.02 ± 0.03, n= 10; TTX/Aβ 24 h = 1.46 ± 0.04; n= 10). g Immunostain-
ings of surface GluA1 (red) and GluA2 (green) after 24 h incubation with the indicated treatments. Scale bar represents 2 μm. h Quantification of changes
in surface synaptic intensity of GluA1 and GluA2 (GluA1: control = 1 ± 0.03, n= 11; Aβ= 0.88 ± 0.03, n =10; TTX = 1.42 ± 0.03, n= 11; TTX/Aβ= 1.63 ± 0.04,
n=11. GluA2: control = 1 ± 0.02, n= 10; Aβ= 0.84 ± 0.04, n =10; TTX = 1.29 ± 0.03, n= 10; TTX/Aβ= 1.39 ± 0.04, n =10). Mann–Whitney U test, * p< 0.05,
** p< 0.01, *** p< 0.001, **** p< 0.0001 ns = not significant
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mediated HSP. The increase in CP-AMPARs after 24 h
inactivity may suggest an Aβ-dependent elongation of
the initiation process, which leads to an over-expression
of CP-AMPARs and thus an elevated recruitment of N-
AMPARs, resulting in HSP over-scaling.
To directly investigate the change in surface AMPAR
composition, we immunostained neurons for surface
synaptic GluA1 and GluA2 after 24h incubation with
Aβ, TTX or TTX/Aβ (Fig. 3g). Aβ incubation alone
produced a modest decrease in both surface GluA1
and GluA2 levels (Fig. 3h) with no significant change
in the ratio of GluA2:GluA1 (Fig. 3i). With the incu-
bation of TTX, we observed a significant increase in
the amount of surface GluA1 and GluA2 compared
to control cells (Fig. 3h), as well as a significant de-
crease in the ratio of GluA2:GluA1 (Fig. 3i) suggest-
ing that both CP-AMPARs and N-AMPARs had been
recruited to the synaptic surface. TTX/Aβ treatment
led to an increase in both GluA1 and GluA2 levels
that were also significantly greater than TTX alone
(Fig. 3h). Additionally, we observed a significant de-
crease in the GluA2:GluA1 ratio after TTX/Aβ treat-
ment compared to TTX treatment alone (Fig. 3i).
These findings corroborate our mEPSC recordings
and indicate that the Aβ-mediated over-scaling of
HSP increases the amount of CP-AMPARs and N-
AMPARs at the synaptic surface.
Aβ produces over-scaling in vivo in mouse visual cortex
after visual deprivation
To determine whether Aβ-mediated over-scaling of HSP
could occur in vivo, we adopted a mouse model for HSP
in the visual cortex with visual deprivation (VD) [11,
18]. In 1 month-old mice, Aβ (10 μg), or vehicle (water),
was injected into V1 visual cortex via a cannula, then bi-
lateral VD was conducted and the animals were kept in
the dark. Following 24 h VD, brain slices of the visual
cortex were prepared for mEPSC recordings to examine
synaptic scaling (Fig. 4a1). Consistent with previous
studies [18, 31], VD was able to induce a significant
homeostatic increase in mEPSC amplitude. We observed
a 19% increase in mEPSC amplitude in VD animals
compared to controls (Fig. 4a2–a3). In line with our
recordings in cultured neurons, Aβ injection alone de-
creased mEPSC amplitude (Fig. 4a2–a3) and frequency
(Additional file 1: Figure S6) compared to vehicle con-
trol animals. However, VD + Aβ produced an overshoot
in the HSP response. Recordings from VD + Aβ treated
animals showed a 36% increase in mEPSC amplitude
compared to control, while VD alone without Aβ
showed a 19% increase compared to control (Fig. 4a2–a3).
Thus, similar to the in vivo findings, Aβ induced an over-
scaling in visual cortical neurons in vivo under activity
suppression conditions.
CP-AMPARs are responsible for Aβ-induced over scaling
in visual cortex
To investigate the contribution of CP-AMPARs to Aβ-
mediated HSP in vivo, we performed visual deprivation
for 24 h after injection of Aβ or vehicle into V1 visual
cortex and recorded mEPSCs from brain slices in the
presence of PhTx (Fig. 4b1). Strikingly, application of
PhTx to brain slices from VD +Aβ animals was sufficient
to return mEPSC amplitudes to levels similar to control
animals without VD (Fig. 4b2–b3). Therefore, in visual
cortex in vivo, the elevated mEPSC amplitude during
HSP was constituted predominantly of CP-AMPARs.
These findings suggest that compared to HSP in cul-
tured neurons, CP-AMPARs are the major component
for HSP expression in vivo.
miR124 is necessary for CP-AMPAR production and
Aβ-induced over scaling
MicroRNA miR124 has been shown to play a key role
for the generation of CP-AMPARs [22, 24]. miR124
selectively binds to the 3’-UTR of GluA2 mRNA sup-
pressing protein expression of GluA2. Probably via
calcium signaling gated by calcium permitting CP-
AMPARs, an increase in miR124, and subsequent forma-
tion of CP-AMPARs is required for the homeostatic
response [24]. To examine miR124 expression, we
treated neuronal cultures with TTX, Aβ, or TTX/Aβ for
6h and collected total RNA. qPCR revealed that miR124
expression was increased 12% in neurons treated with
Aβ alone, comparing to a 72% increase in neurons incu-
bated with TTX (Fig. 5a). Surprisingly, co-incubation of
TTX with Aβ produced a 97% increase in miR124 that
was significantly larger than TTX or Aβ alone (Fig. 5a).
These results indicate that under a condition of activity
suppression, Aβ is capable of dramatically up-regulating
miR124 expression in neurons, which presumably leads
to the generation of a higher amount of CP-AMPARs
for HSP expression.
To examine the necessity of miR124 in Aβ-mediated
HSP, we transfected hippocampal neurons with a
miR124-binding sponge (BS) construct to neutralize
endogenous miR124 [24]. The sponge consisted of two
tandem repeats of a sequence complementary to miR124,
so that when overexpressed, it would bind and sequester
miR124. The miR124-BS has previously been validated
to block the initiation of TTX induced HSP [24]. We
found that expression of the miR124-BS not only
blocked HSP by TTX, but also HSP over-scaling in-
duced by TTX/Aβ, indicating that the up-regulation of
miR124 was required for HSP (Fig. 5b), presumably
due to a suppression of CP-AMPAR formation. Add-
itionally, expression of the miR124-BS with Aβ showed
an ~10% decrease in amplitude, similar to treatment
with Aβ + GFP (Fig. 5b).
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Aβ destabilizes the association between EV1 and HDAC1
The transcription factor EVI1 has been shown to regulate
miR124 expression by binding to the regulatory region of
the miR124 gene to suppress its transcription [12, 49, 57].
Association of EVI1 with the histone deacetylase HDAC1 is
crucial for transcriptional repression via histone deacetyla-
tion [4, 20]. Importantly, a decreased EV1-HDAC1 inter-
action has been shown to be controlled by neuronal activity
and to control miR124 expression [24]. We hypothesized
that treatment with Aβ during activity deprivation could
further decrease the EVI1-HDAC1 interaction, thereby in-
creasing miR124 levels. We therefore immunoprecipitated
EVI1 from lysates of cultured cortical neurons after treat-
ment with TTX or TTX/Aβ for 24 h and probed for
HDAC1. Indeed, activity deprivation by TTX caused a re-
duction in the EVI1–HDAC1 interaction, and association
was further reduced with the TTX/Aβ treatment (Fig. 5c
and 5d), consistent with the idea that a destabilization of
the EVI1-HDAC1 association by Aβ resulted in elevated
miR124 expression.
miR124 is required for Aβ-induced over-scaling in vivo
Next, we wanted to examine whether miR124 was impli-
cated in the aberrant over-scaling in vivo First, we found
that following Aβ injection in the visual cortex and 24 h
VD, qPCR confirmed a 110% increase in miR124 expres-
sion compared to vehicle controls (Fig. 5e). To confirm the
role of miR124 in HSP in vivo, we injected miR124 inhibi-
tor virus, or a scrambled control, one month prior to VD
experiments to allow for viral expression. Mice were then
injected with vehicle or Aβ, into the visual cortex followed
by 24 h VD. mEPSC recordings from visual cortical brain
slices showed that knockdown of miR124 in vivo blocked
VD-induced HSP in both vehicle and Aβ treated animals
(Fig. 5f-g), indicating that miR124 expression is necessary
for normal and over-scaling of HSP in vivo.
Fig. 4 Aβ-mediated over-scaling in vivo requires CP-AMPARs. a1 Bilateral VD was performed in one month-old mice by sealing the eyelids with
black epoxy and the animals were then kept in the dark. Prior to VD, Aβ (10 μg) or vehicle (water) was injected into V1 visual cortex via a cannula.
Following 24 h VD, brain slices of the visual cortex were prepared for mEPSC recordings to examine synaptic scaling. a2 Sample mEPSC traces
from brain slice recordings after the treatments shown to A1. a3 Quantification of the data shown in A2 (Control no VD = 12.2 ± 0.23, n = 7; Aβ
no VD= 10.2 ± 0.48, n =6; Control after VD = 14.5 ± 0..19, n = 6; Aβ after VD = 16.6 ± 0.63, n = 6; 4 mice per condition). b1 Following 24 h VD paradigm,
mEPSCs were recorded from brain slices with, or without PhTx, to determine the contribution of CP-AMPARs to HSP in vivo. b2 Sample mEPSC traces
from brain slice recordings after the treatments shown to B1. b3 Quantification of the data shown in B2 (Control no VD+ PhTx = 11.5 ± 0.33, n = 5; Aβ
no VD+ PhTx = 7.68 ± 0.21, n = 5; Control after VD + PhTx = 10.9 ± 0.21, n = 6; Aβ after VD + PhTx = 8.2 ± 0.63, n = 5; 4 mice per condition). Mann–Whit-
ney U test, * p < 0.05, ** p < 0.01, *** p < 0.001, ns = not significant
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Fig. 5 (See legend on next page.)
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Discussion
For the first time, we provide evidence indicating a role
for Aβ in homeostatic synaptic regulation, a mechanism
counter-balancing Hebbian synaptic plasticity and cru-
cial for the stabilization of neuron and neural circuit
activity. During normal conditions, activity suppression
triggers HSP thereby returning synaptic activity to a
physiological level. However, in the presence of Aβ,
neuronal inactivity triggered an overshoot in the HSP
response, producing an aberrant over-scaling of synaptic
strength (Fig. 5h). Our findings strongly support a role
of altered homeostatic plasticity in AD, a hypothesis that
has previously been proposed by Small [51, 52].
The increased synaptic scaling was caused by a larger
and more prolonged expression of CP-AMPARs during
the course of HSP. An increase in the generation of CP-
AMPARs was observed as a result of an increase in
miR124 expression after Aβ treatment, both in rat hippo-
campal neurons in vivo and mouse visual cortex in vivo.
Although miR124 facilitates the expression of HSP, an
increase in expression of miR124 alone is not sufficient to
induce a homeostatic response [24]. From our findings,
Aβ induces a destabilization of the EV1-HDAC1 inter-
action, thereby allowing for more miR124 transcription
and subsequent generation of CP-AMPARs. This could
possibly prime the system such that during activity block-
ade an abnormal overshoot in the HSP response can be
triggered. In addition to miR124-dependent generation
of CP-AMPARs, Aβ may remove GluA2-containing
AMPARs from synapses preferentially thereby promot-
ing the HSP response.
HSP serves to maintain neuronal networks within a
physiological range while conserving individual synaptic
weights. With an Aβ-mediated over-scaling of HSP, the
network could destabilize, or individual synaptic responses
could become saturated, thereby disrupting information
processing and contributing to memory deficits. Poten-
tially, synaptic over-scaling by Aβ could lead to an in-
crease in the overall excitability in a local neural network.
Indeed, epidemiological studies have shown that AD con-
fers an increased risk of seizures and epilepsy, with about
a sevenfold increase in seizure incidences in AD patients
compared to normal controls [27]. While seizures can
appear at any stage of the disease, epileptiform activity is
highest in younger AD patients earlier in the disease pro-
gression [1, 28]. In AD transgenic mice, elevated levels of
Aβ correlate with a higher incidence of seizures before
evidence of neuronal loss [45]. Mechanisms that underlie
AD-related seizures remain unclear, but HSP over-scaling
may represent a causal factor. Additionally, since synaptic
release of Aβ is stimulated by neuronal activity, increased
synaptic activity could create a positive feedback loop that
accelerates AD progression [44, 51, 52].
In line with our findings, HSP of excitatory synapses
has been shown to be impaired in neurons lacking
presinilin 1 (PS1−/−) or neurons expressing a familial
AD-linked mutation (PS1M146V), which was not dependent
on γ-secretase activity and showed impaired phos-
phatidylinositol 3-kinase (PI3K)/Akt signaling [46]. These
findings suggest that other mechanisms may have dif-
ferent effects on HSP in AD and indicate that aber-
rant synaptic scaling may play a role in familial as
well as sporadic AD.
There is a growing body of evidence implicating
CP-AMPARs during the onset of synaptic pathology
in neurological disorders [21, 35, 47, 60]. Previous
analyses of hippocampal postsynaptic density fractions
from human AD patients showed an increase in
GluA1 levels compared to healthy controls, whereas no
changes in NMDAR subunit expression were observed
(See figure on previous page.)
Fig. 5 miR124 expression is increased in Aβ-mediated over-scaling due to a decreased EVI1-HDAC1 interaction. a MicroRNAs were purified from
rat hippocampal lysates treated for 24 h with the conditions shown and miR124 was quantified by qRT-PCR (Control = 1 ± 0.02, n = 3; Aβ = 1.12 ±
0.02, n =3; TTX = 1.72 ± 0.03, n = 3; TTX/Aβ = 1.97 ± 0.02, n =3). Values normalized to control, error bars = ± SEM. b Hippocampal neurons were
transfected with a miR124 BS (containing GFP) or a scrambled BS-GFP for 1 day followed by 24 h treatment with the conditions shown. mEPSC
amplitudes were increased in the scrambled BS controls but not in the miR124 BS transfected cells (Control + GFP = 12.33 ± 0.86, n = 3; Aβ + GFP
= 10.2 ± 0.97, n =3; TTX + GFP = 16.8 ± 0.62, n = 3; TTX/Aβ + GFP = 19.5 ± 0.74, n =3; Control + BS = 12.9 ± 0.74, n =8; Aβ + BS = 9.9 ± 0.83, n =3; TTX
+ BS = 11.8 ± 0.86, n =9; TTX/Aβ + BS = 12.9 ± 0.86, n =8; 4 mice per condition). c Co-immunoprecipitation of EVI1 and HDAC1. Using lysates from
rat cortical neurons incubated with the conditions shown for 24 h, EVI1 complexes were isolated by immunoprecipitation and probed for HDAC1.
EVI1 co-immunoprecipitated with HDAC1 and the association was further decreased by incubation with TTX/Aβ. d Quantification of the co-
immunoprecipitation data from C (n = 4); HDAC1 was normalized to the immunoprecipitated EVI1 levels. e MicroRNAs were purified from mouse
cortex 24 h after injection of Aβ (10μg) or vehicle control and miR124 was quantified by qRT-PCR (Control = 1.01 ± 0.13, n =10; Aβ = 2.12 ± 0.25,
n = 10). Values normalized to control, error bars = ± SEM. f Sample mEPSC traces from recordings in V1 visual cortex for the treatments shown.
g Quantification of the traces shown in E. mEPSC amplitudes were increased in the scrambled siRNA controls for VD and VD + Aβ but not in the
miR124 siRNA infected cells (no VD + scr siRNA = 11.7 ± 0.52, n = 6; VD + scr siRNA = 14.1 ± 0.23, n =8; VD + Aβ + scr siRNA = 16.1 ± 0..57, n = 5; no
VD +miR124 siRNA = 11.4 ± 0.33, n =6; VD +miR124 siRNA = 10.1 ± .62, n = 5; VD + Aβ +miR124 siRNA = 10.3 ± .36, n =6; 4 mice per condition).
h Model depicting the disruption of HSP by Aβ. During initiation, both TTX and TTX/Aβ show a normal increase in CP-AMPARs (solid lines),
however in the presence of Aβ, CP-AMPAR expression continues to increase subsequently driving a further increase in N-AMPARs and total
AMPARs (dashed lines) during the expression phase of HSP. Mann–Whitney U test, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.001, ns = not
significant. Values =mean, error bars = ± SEM
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[41], suggesting a selective increase in GluA1-containing
receptors in the hippocampus of AD patients. Consist-
ent with this, aberrant CP-AMPAR expression and in-
creased GluA1 phosphorylation have been reported in
young mice, prior to any neuropathology, in an AD
transgenic mouse model [42]. Together, these findings
support a mechanism in which increased CP-AMPAR
synaptic insertion during the early stages of AD
pathogenesis leads to later synaptic pathologies. In
addition, given the unique property that CP-AMPARs
have a high permeability to calcium, it is intriguing to
postulate an additional role of the CP-AMPARs
expressed during HSP in neuronal death during the
later stages of AD. Therefore, the CP-AMPAR as well
as the HSP regulation cascade could serve as a thera-
peutic target in the development of new treatments
in AD.
Conclusions
Homeostatic synaptic plasticity (HSP) serves to maintain
neuronal and network activity within a physiological
range by regulating AMPAR synaptic abundance and
thus scaling synaptic activity. We report for the first
time that during neuronal inactivity, Aβ application pro-
duces an aberrant over-scaling of AMPA receptor
(AMPAR)-mediated mEPSCs in both neuronal cultures
and in the brain in vivo in a model of visual deprivation.
Via stimulating miR124 expression, Aβ results in bio-
genesis of GluA2-lacking, calcium-permeable AMPARs
(CP-AMPARs), which are required for HSP initiation.
The aberrant over-scaling effect of Aβ may underlie
the unbalanced neuronal network activity and seizures
observed in the early phases of AD, as well as neur-
onal death and cognitive dysfunction in the later
phases of AD.
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